ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

Company Overview

ASLAN Pharmaceuticals Ltd is a clinical‐stage biotechnology company focused on the discovery and development of novel immunology and oncology therapies. The company leverages proprietary antibody and small‐molecule platforms to address critical biological targets involved in tumor immune evasion and inflammatory disease pathways. ASLAN’s R&D approach combines modern protein engineering, antibody-drug conjugates and precision small‐molecule design to generate next‐generation therapeutics.

The company’s lead clinical programs include ASLAN003, an orally available allosteric IRAK4 inhibitor designed to modulate innate immune signaling in severe inflammatory diseases, and ASLAN004, a high-affinity nanobody targeting the CD39 ectonucleotidase to reinvigorate anti-tumor immune responses. In addition to these assets, ASLAN is advancing a diversified preclinical pipeline that features antibody-drug conjugates for solid tumors and multi-specific antibody formats aimed at difficult-to-treat cancers.

Founded in Singapore in 2015, ASLAN has established operations across Asia, Australia and the United States to support global clinical development. The company completed its initial public offering on the Nasdaq in 2020 and maintains a management team with extensive leadership experience in biopharmaceutical research, regulatory affairs and commercial strategy. ASLAN continues to pursue strategic partnerships and clinical collaborations to accelerate its programs toward regulatory milestones and potential market authorization.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.60 to $0.60
• 52-Week Range: $0.48 to $25.44
• Volume: N/A
• Average Volume: 122,322 shs
• Market Capitalization: $1.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASLN Stock Analysis - Frequently Asked Questions

How have ASLN shares performed this year?

ASLAN Pharmaceuticals' stock was trading at $0.60 at the beginning of the year. Since then, ASLN shares have increased by 0.0% and is now trading at $0.60.

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) released its earnings results on Friday, August, 11th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($6.40) by $5.52. The firm earned $12 million during the quarter.

When did ASLAN Pharmaceuticals' stock split?

Shares of ASLAN Pharmaceuticals reverse split on the morning of Wednesday, July 3rd 2024.The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did ASLAN Pharmaceuticals IPO?

ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ASLAN Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 9/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASLN
• CIK: 1722926
• Web: www.aslanpharma.com
• Phone: 65-6817-9598
• Fax: 65-6225-2419
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.22 million
• Net Margins: N/A
• Pretax Margin: -290.83%
• Return on Equity: -8,454.87%
• Return on Assets: -121.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: $12 million
• Price / Sales: 0.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.50) per share
• Price / Book: -0.09

Miscellaneous

• Outstanding Shares: 2,044,000
• Free Float: 1,948,000
• Market Cap: $1.23 million
• Optionable: Optionable
• Beta: 1.40